Diagnostic value of ACTH stimulation test in determining the subtypes of primary aldosteronism

Journal of Clinical Endocrinology and Metabolism

Volumn 100, Issue 5, 2015, Pages 1837-1844

  Jiang, Yiran ^a,b   Zhang, Cui ^a,b   Wang, Weiqing ^a,b   Su, Tingwei ^a,b   Zhou, Weiwei ^a,b   Jiang, Lei ^a,b   Zhu, Wei ^a,b   Xie, Jing ^b   Ning, Guang ^a,b  

^a Shanghai Institute of Endocrine and Metabolic Diseases   (China)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; HYDROCORTISONE; CORTICOTROPIN;

ADRENAL HYPERPLASIA; ADULT; ALDOSTERONE BLOOD LEVEL; ARTICLE; CONTROLLED STUDY; CORTICOTROPIN TEST; DEXAMETHASONE SUPPRESSION TEST; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DISEASE CLASSIFICATION; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYDROCORTISONE BLOOD LEVEL; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PRIMARY HYPERALDOSTERONISM; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; ADENOMA; ADRENAL CORTEX NEOPLASMS; ADRENAL GLAND; ADRENAL HYPERPLASIA, CONGENITAL; BLOOD; DIAGNOSTIC USE; DIFFERENTIAL DIAGNOSIS; ENDOCRINE FUNCTION TEST; HYPERALDOSTERONISM; MIDDLE AGED; PATHOLOGY;

ADENOMA; ADRENAL CORTEX NEOPLASMS; ADRENAL GLANDS; ADRENAL HYPERPLASIA, CONGENITAL; ADRENOCORTICOTROPIC HORMONE; ADULT; ALDOSTERONE; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; HYPERALDOSTERONISM; MALE; MIDDLE AGED; PITUITARY-ADRENAL FUNCTION TESTS; SENSITIVITY AND SPECIFICITY;

EID: 84929359422     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2014-3551     Document Type: Article

References (35)

1. Conn JW, Louis LH. Primary aldosteronism: a new clinical entity. Trans Assoc Am Physicians. 1955;68:215-231; discussion, 231- 233.
2. Sechi LA, Novello M, Lapenna R, et al. Long-term renal outcomes in patients with primary aldosteronism. JAMA. 2006;295:2638-2645.
3. Savard S, Amar L, Plouin PF, Steichen O. Cardiovascular complications associated with primary aldosteronism: a controlled crosssectional study. Hypertension. 2013;62:331-336.
4. Funder JW, Carey RM, Fardella C, et al. Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2008; 93:3266-3281.
5. Rossi GP, Bernini G, Caliumi C, et al. A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. J Am Coll Cardiol. 2006;48:2293-2300.
6. Fardella CE, Mosso L, Gomez-Sanchez C, et al. Primary hyperaldosteronism in essential hypertensives: prevalence, biochemical profile, and molecular biology. J Clin Endocrinol Metab. 2000;85: 1863-1867.
7. Loh KC, Koay ES, Khaw MC, Emmanuel SC, Young WF, Jr. Prevalence of primary aldosteronism among Asian hypertensive patients in Singapore. J Clin Endocrinol Metab. 2000;85:2854-2859.
8. Fogari R, Preti P, Zoppi A, Rinaldi A, Fogari E, Mugellini A. Prevalence of primary aldosteronism among unselected hypertensive patients: a prospective study based on the use of an aldosterone/renin ratio above 25 as a screening test. Hypertens Res. 2007;30:111-117.
9. Sang X, Jiang Y, Wang W, et al. Prevalence of and risk factors for primary aldosteronism among patients with resistant hypertension in China. J Hypertens. 2013;31:1465-1471; discussion 1471-1472.
10. Young WF. Primary aldosteronism: renaissance of a syndrome. Clin Endocrinol (Oxf). 2007;66:607-618.
11. Sigurjonsdottir HA, Gronowitz M, Andersson O, et al. Unilateral adrenal hyperplasia is a usual cause of primary hyperaldosteronism. Results from a Swedish screening study. BMC Endocr Disord. 2012; 12:17.
12. Iacobone M, Citton M, Viel G, et al. Unilateral adrenal hyperplasia: a novel cause of surgically correctable primary hyperaldosteronism. Surgery. 2012;152:1248-1255.
13. Shimamoto K, Ando K, Fujita T, et al. The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2014). Hypertens Res. 2014;37:253-387.
14. Rossi GP, Auchus RJ, Brown M, et al. An expert consensus statement on use of adrenal vein sampling for the subtyping of primary aldosteronism. Hypertension. 2014;63:151-160.
15. Kem DC, Weinberger MH, Higgins JR, Kramer NJ, Gomez-Sanchez C, Holland OB. Plasma aldosterone response to ACTH in primary aldosteronism and in patients with low renin hypertension. J Clin Endocrinol Metab. 1978;46:552-560.
16. Stowasser M, Klemm SA, Tunny TJ, Gordon RD. Plasma aldosterone response to ACTH in subtypes of primary aldosteronism. Clin Exp Pharmacol Physiol. 1995;22:460-462.
17. Seccia TM, Miotto D, De Toni R, et al. Adrenocorticotropic hormone stimulation during adrenal vein sampling for identifying surgically curable subtypes of primary aldosteronism: comparison of 3 different protocols. Hypertension. 2009;53:761-766.
18. Mulatero P, Milan A, Fallo F, et al. Comparison of confirmatory tests for the diagnosis of primary aldosteronism. J Clin Endocrinol Metab. 2006;91:2618-2623.
19. Tiu SC, Choi CH, Shek CC, et al. The use of aldosterone-renin ratio as a diagnostic test for primary hyperaldosteronism and its test characteristics under different conditions of blood sampling. J Clin Endocrinol Metab. 2005;90:72-78.
20. Maniero C, Fassina A, Seccia TM, et al. Mild hyperparathyroidism: a novel surgically correctable feature of primary aldosteronism. J Hypertens. 2012;30:390-395.
21. Nanba K, Tsuiki M, Sawai K, et al. Histopathological diagnosis of primary aldosteronism using CYP11B2 immunohistochemistry. J Clin Endocrinol Metab. 2013;98:1567-1574.
22. Volpe C, Hamberger B, Hoog A, et al. Primary aldosteronism: functional histopathology and long-term follow-up after unilateral adrenalectomy. Clin Endocrinol (Oxf). 2014.
23. Lin YH, Lee HH, Liu KL, et al. Reversal of myocardial fibrosis in patients with unilateral hyperaldosteronism receiving adrenalectomy. Surgery. 2011;150:526-533.
24. Goh BK, Tan YH, Chang KT, Eng PH, Yip SK, Cheng CW. Primary hyperaldosteronism secondary to unilateral adrenal hyperplasia: an unusual cause of surgically correctable hypertension. A review of 30 cases. World J Surg. 2007;31:72-79.
25. Hennings J, Andreasson S, Botling J, Hagg A, Sundin A, Hellman P. Long-term effects of surgical correction of adrenal hyperplasia and adenoma causing primary aldosteronism. Langenbecks Arch Surg. 2010;395:133-137.
26. Willenberg HS, Schinner S, Ansurudeen I. New mechanisms to control aldosterone synthesis. Horm Metab Res. 2008;40:435-441.
27. Williams GH. Aldosterone biosynthesis, regulation, and classical mechanism of action. Heart Fail Rev. 2005;10:7-13.
28. Gallo-Payet N, Grazzini E, Cote M, et al. Role of Ca2+ in the action of adrenocorticotropin in cultured human adrenal glomerulosa cells. J Clin Invest. 1996;98:460-466.
29. Mazzocchi G, Malendowicz LK, Macchi C, Gottardo G, Nussdorfer GG. Further investigations on the effects of neuropeptide Y on the secretion and growth of rat adrenal zona glomerulosa. Neuropeptides. 1996;30:19-27.
30. Bornstein SR, Chrousos GP. Clinical review 104: adrenocorticotropin (ACTH)- and non-ACTH-mediated regulation of the adrenal cortex: neural and immune inputs. J Clin Endocrinol Metab. 1999; 84:1729-1736.
31. Arnaldi G, Mancini V, Costantini C, et al. ACTH receptor mRNA in human adrenocortical tumors: overexpression in aldosteronomas. Endocr Res. 1998;24:845-849.
32. Schubert B, Fassnacht M, Beuschlein F, Zenkert S, Allolio B, Reincke M. Angiotensin II type 1 receptor and ACTH receptor expression in human adrenocortical neoplasms. Clin Endocrinol (Oxf). 2001;54:627-632.
33. Ye P, Mariniello B, Mantero F, Shibata H, Rainey WE. G-protein-coupled receptors in aldosterone-producing adenomas: a potential cause of hyperaldosteronism. J Endocrinol. 2007;195:39-48.
34. Zwermann O, Suttmann Y, Bidlingmaier M, Beuschlein F, Reincke M. Screening for membrane hormone receptor expression in primary aldosteronism. Eur J Endocrinol. 2009;160:443-451.
35. Sonoyama T, Sone M, Miyashita K, et al. Significance of adreno-corticotropin stimulation test in the diagnosis of an aldosteroneproducing adenoma. J Clin Endocrinol Metab. 2011;96:2771-2778.